Haleon (HLN) Gross Margin (2021 - 2023)

Haleon (HLN) recorded quarterly Gross Margin of 61.33% in Q4 2023, down 1.3% on a QoQ basis from 62.14% in Q2 2023, and down 791.0% year-over-year from 8.88% in Q4 2022.

Haleon (HLN) Gross Margin (2021 - 2023) Analysis & Trends

Haleon has disclosed Gross Margin across 3 years of filings, most recently posting 61.33% for Q4 2023.

  • Quarterly Gross Margin fell 791.0% year-over-year to 61.33% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 63.4% (changed N/A YoY) and the FY2025 annual result came in at 64.19%, up 344.0% from the prior year.
  • Gross Margin eased to 61.33% in Q4 2023, from 62.14% in the prior quarter.
  • Over five years, Gross Margin peaked at 69.24% in Q4 2022 and troughed at 61.33% in Q4 2023.
  • A 3-year average of 63.37% and a median of 62.14% in 2023 frame the typical range for Gross Margin.
  • Annual changes were most pronounced in 2022 — Gross Margin soared 671 bps — and 2023, when it tumbled 791 bps.
  • Tracing HLN's Gross Margin over 3 years: stood at 62.53% in 2021, then grew by 11 bps to 69.24% in 2022, then decreased by 11 bps to 61.33% in 2023.
  • Business Quant data shows HLN's Gross Margin at 61.33% in Q4 2023, 62.14% in Q2 2023, and 61.62% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 49.52%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 71.66%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 82.93%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 49.50%
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 98.31%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 57.26%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -293.83%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 65.25%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 61.20%
10 Haleon 1.09 Bn -773.69 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 61.33%
Jun 30, 2023 62.14%
May 3, 2023 61.62%
Dec 31, 2022 69.24%
Dec 31, 2021 62.53%